How this works
CJC-1295 no DAC stimulates pulsatile GH release through GHRH receptor activity, while Ipamorelin selectively stimulates GH release through GHS pathways without the same cortisol or ACTH emphasis seen with some older secretagogues.
Back to library
GH Secretagogue Blend
CJC-1295 No DAC + Ipamorelin
A growth-hormone secretagogue research blend combining a GHRH analog with a selective GHS peptide for pulsatile GH-pathway studies.
Vial
10 mg blend, 5 mg each
Category
GH Secretagogue Blend
Research highlights
A blend combining a GHRH analog with a selective GH secretagogue.
Studied for complementary GHRH and GHS signaling pathways.
Ipamorelin is characterized as a selective GHS in the literature.
Storage
- Lyophilized: store frozen around −20 °C.
- Reconstituted: refrigerate at 2–8 °C and use within about 28 days.
- Protect from light and avoid repeated freeze–thaw cycles.
Research-use notice
⚠️ All peptides on this site are not FDA approved and are not approved for human use outside of a clinical trial. f4Labs presents this material as a research reference only — not medical advice, diagnosis, or treatment guidance.
Peer-Reviewed References
Mechanism descriptions and research context are informed by the following published literature. Click any citation to view the source.
- 1Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. doi:10.1210/jc.2005-1995.View source
- 2Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. doi:10.1530/eje.0.1390552.View source
- 3Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998. doi:10.1210/jcem.83.2.4539.View source